Table 1. Quantification of Sugar-Sensitive LSBPs in Five Cancer Cell Lines.
| Suit2-007, n (%)a | ASML, n (%)a | BXPC3, n (%)a | MCF7, n (%)a | LST, n (%)a | |
|---|---|---|---|---|---|
| Total LSBPsb | 1593 | 1955 | 1208 | 1365 | 526 |
| Lacc | 432 (27.1) | 364 (18.6) | 401 (33.2) | 373 (27.3) | 215 (41.0) |
| Gald | 699 (43.9) | 472 (24.1) | 365 (30.2) | 365 (26.7) | 163 (31.0) |
| Glce | 497 (31.2) | 209 (10.7) | 307 (25.4) | 301 (22.0) | 135 (25.6) |
| Rhaf | 260 (16.3) | 151 (7.7) | 174 (14.4) | 155 (11.4) | 129 (24.5) |
a
Cancer cell lines used for extraction of LSBPs: Suit2-007, ASML, BXPC3 (pancreatic cancer), MCF7 (breast cancer) and LST (colon cancer).
b
The number of LSBPs quantified per cell line.
c
Lactose,
d
galactose,
e
glucose and
f
rhamnose represent the sugars added to the mobile phase to inhibit the binding of LSBPs by competition. n (%) represents the number and relative percentage of sugar-sensitive LSBPs prevented from binding to the resin in the presence of each sugar.